Press Releases

Date Title and Summary Additional Formats
Toggle Summary Amicus Therapeutics Announces Full-Year 2018 Financial Results and 2019 Corporate Updates
Continued Strong Galafold Launch Trends in Early 2019 - On Track to Achieve FY19 Revenue Guidance of $160M-$180M FY18 Galafold Revenue of $91.2M Reflects 650+ Fabry Patients Treated at end of 2018 - 1,000+ Patients Expected by end of 2019 Clinical Data Out to Month 24 and Breakthrough Therapy
View HTML
Toggle Summary Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia
New 75,000 sq. ft. State of the Art Facility in uCity Square Adjacent to Penn Campus Strengthens Amicus Capabilities as a Leading Global Rare Disease Biotechnology Company CRANBURY, N.J. and PHILADELPHIA , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced it is
View HTML
Toggle Summary U.S. FDA Grants Breakthrough Therapy Designation (“BTD”) to Amicus’ AT-GAA in Late Onset Pompe Disease
First BTD Granted for a Second Generation Lysosomal Storage Disorder Therapy First BTD for an Investigational Treatment in Pompe Disease CRANBURY, N.J. , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S.
View HTML
Toggle Summary Amicus Therapeutics to Announce Full-Year 2018 Financial Results on February 28, 2019
CRANBURY, N.J. , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, February 28, 2019 at 8:30 a.m. ET to discuss financial results for the full year ended December 31, 2018 .
View HTML
Toggle Summary Amicus Therapeutics Announces Positive data in Pompe Disease Phase 1/2 Study for Up to 24 Months at 15th Annual WORLDSymposium™
Consistent and Durable Responses Across Key Measures of Safety, Functional Outcomes and Biomarkers Continue for both ERT-Naïve and ERT-Switch Patients Patient Reported Outcomes Data Demonstrate Benefits in Activities of Daily Living and Patient Well Being for AT-GAA Treated Patients Detailed
View HTML
Toggle Summary Amicus Therapeutics Announces Presentations and Posters at 15th Annual WORLDSymposium™ 2019
CRANBURY, N.J. , Jan. 18, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced that four oral presentations and eight posters highlighting its
View HTML
Toggle Summary Amicus Therapeutics Provides Full-Year 2019 Strategic Outlook and Financial Guidance
Full-Year 2018 Galafold Revenue of ~$91M Exceeds $80M-$90M Guidance 2019 Galafold Revenue Expected to Nearly Double – with Guidance of $160M-$180M Pompe Phase 3 PROPEL Study Expected to Complete Enrollment and Additional Phase 2 Pompe Data in 2019 Additional 2-Year Data from Phase 1/2 CLN6 Batten
View HTML
Toggle Summary Amicus Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
CRANBURY, N.J. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John F. Crowley, Chairman and Chief Executive Officer, will present a corporate overview at the 37 th  Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Tuesday, January 8,
View HTML
Toggle Summary Amicus Therapeutics Announces Phase 1/2 Study of Gene Therapy for CLN3 Batten Disease
Second Gene Therapy to Enter Clinic at Nationwide Children’s Hospital for Neurologic Lysosomal Storage Disorders Initial Safety is Encouraging with No Serious Adverse Events at One Month CRANBURY, N.J. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology
View HTML
Toggle Summary Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
Global Study to Assess AT-GAA Compared to Standard-of-Care Enzyme Replacement Therapy (ERT) over 52 Weeks CRANBURY, N.J. , Dec. 20, 2018 (GLOBE NEWSWIRE) --   Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for
View HTML